相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Felipe Batalini et al.
CLINICAL CANCER RESEARCH (2022)
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
F. Cardoso et al.
ANNALS OF ONCOLOGY (2022)
Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
Fabrice Andre et al.
CANCER RESEARCH (2022)
Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<= 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Stephen Chia et al.
CANCER RESEARCH (2022)
Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
Dejan Juric et al.
CANCER RESEARCH (2022)
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W. Song et al.
CANCER DISCOVERY (2022)
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Emily J. Hanan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines
Maria Rosaria Ambrosio et al.
CANCERS (2022)
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu et al.
CLINICAL CANCER RESEARCH (2021)
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
Triplet Therapy with Palbociclib, Taselisib, and fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual et al.
CANCER DISCOVERY (2021)
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H. P. Eikesdal et al.
ANNALS OF ONCOLOGY (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors
Yanyan Cai et al.
CANCER RESEARCH (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer
Elisa Agostinetto et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Eva Maria Ciruelos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
Sarah Christine Elisabeth Wright et al.
CANCERS (2021)
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
Huayu Hu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
POSEIDON randomized phase II trial: Tamoxifen (TAM) plus taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC)
M. Oliveira et al.
ANNALS OF ONCOLOGY (2021)
Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Jorge Gomez Tejeda Zanudo et al.
CANCER RESEARCH (2021)
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
Clinical Trial
Giuseppe Curigliano et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis
John Hang Leung et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
David Starks et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.
Diana Bello et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer
Lea E. Mollon et al.
CLINICAL BREAST CANCER (2020)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
Sean P. Kennedy et al.
ONCOGENE (2020)
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2020)
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Sanxing Guo et al.
CANCER RESEARCH AND TREATMENT (2020)
Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis
Yiqun Han et al.
CURRENT PROBLEMS IN CANCER (2020)
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K. Ramanathan et al.
TARGETED ONCOLOGY (2020)
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M. Litchfield et al.
Oncotarget (2020)
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
Anja Welt et al.
CANCER MEDICINE (2020)
EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
S. A. Hurvitz et al.
ANNALS OF ONCOLOGY (2020)
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
Shu Wang et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Pedram Razavi et al.
NATURE CANCER (2020)
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2019)
Mechanisms of PTEN loss in cancer: It's all about diversity
Virginia Alvarez-Garcia et al.
SEMINARS IN CANCER BIOLOGY (2019)
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
Sarah Sammons et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G. Abramson et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird et al.
CLINICAL CANCER RESEARCH (2019)
TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura et al.
LANCET ONCOLOGY (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2019)
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Dejan Juric et al.
JAMA ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
Ana Ruiz-Saenz et al.
CANCER RESEARCH (2018)
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer
Autumn J. McRee et al.
CLINICAL BREAST CANCER (2018)
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2018)
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis
Navid Sobhani et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2018)
Mechanisms Behind Resistance to P13K Inhibitor Treatment Induced by the PIM Kinase
Jin H. Son et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
Marcus D. Goncalves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schoffski et al.
BREAST CANCER RESEARCH (2018)
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
Sarah R. Hosford et al.
CLINICAL CANCER RESEARCH (2017)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl et al.
EUROPEAN JOURNAL OF CANCER (2017)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric et al.
CANCER DISCOVERY (2017)
A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC).
Otto Metzger Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo et al.
CANCER RESEARCH (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Dejan Juric et al.
CLINICAL CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
A phase lb study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer
Jose Baselga et al.
CANCER RESEARCH (2016)
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Xiuning Le et al.
CANCER DISCOVERY (2016)
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER/HER2 advanced breast cancer (ABC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
Carlotta Costa et al.
CANCER CELL (2015)
Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer
Cristina Saura et al.
CANCER RESEARCH (2015)
Metabolic Reprogramming of Immune Cells in Cancer Progression
Subhra K. Biswas
IMMUNITY (2015)
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations
Mara A. Bonelli et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Synergy in activating class I PI3Ks
John E. Burke et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
PI3K mutations in breast cancer: prognostic and therapeutic implications
Toru Mukohara
BREAST CANCER-TARGETS AND THERAPY (2015)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien et al.
CLINICAL CANCER RESEARCH (2014)
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon et al.
INVESTIGATIONAL NEW DRUGS (2014)
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Ingrid A. Mayer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis
Bo Pang et al.
SCIENTIFIC REPORTS (2014)
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Violeta Serra et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
Chudi O. Ndubaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
Hiromichi Ebi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients
Flavia R. Mangone et al.
CLINICS (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Leiping Wang et al.
BMC CANCER (2011)
Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy
Yuting Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform
Timothy P. Heffron et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
A. Chakrabarty et al.
ONCOGENE (2010)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The role of PTEN signaling perturbations in cancer and in targeted therapy
M. Keniry et al.
ONCOGENE (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
Mattia Barbareschi et al.
CLINICAL CANCER RESEARCH (2007)
Mutation of the PIK3CA oncogene in human cancers
B Karakas et al.
BRITISH JOURNAL OF CANCER (2006)
Oncogenic PI3K and its role in cancer
Y Samuels et al.
CURRENT OPINION IN ONCOLOGY (2006)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
分享论文
